PYC pyc therapeutics limited

Hi Tony,In reading through the Chairman's Report I completely...

  1. 1,553 Posts.
    lightbulb Created with Sketch. 2333
    Hi Tony,
    In reading through the Chairman's Report I completely overlooked the significance of the recent deal with Cubist Pharmaceuticals. Firstly, the top of Page 5 highlights Phylogica's strategy to monetise non-core assets including antimicrobial peptides which is "available for out-licensing". Directly below is a report on the Cubist deal. Cubist are evaluating several of our antimicrobial peptides.

    Initially, there was some disappointment by shareholders that Cubist didn't enter into a collaborative arrangement with Phylogica similar to the Janssen deal. It would appear, however, that Cubist has simply gone to the head of the queue and are evaluating our in-house antimicrobial program with the intention of licensing promising leads. Our first licensing deal may be closer than what we thought.

    Wayne.
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
$1.28
Change
-0.040(3.03%)
Mkt cap ! $746.5M
Open High Low Value Volume
$1.32 $1.35 $1.28 $764.7K 579.2K

Buyers (Bids)

No. Vol. Price($)
1 4000 $1.28
 

Sellers (Offers)

Price($) Vol. No.
$1.30 40248 3
View Market Depth
Last trade - 16.10pm 04/07/2025 (20 minute delay) ?
PYC (ASX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.